Peps
What is PE-22-28?
PE-22-28 is a seven-amino-acid peptide designed from spadin, a naturally occurring fragment of the sortilin propeptide. Its published evidence comes from cell-channel experiments and mouse behavior tests, not studies in people.
Biological role or research focus
TREK-1 blockade in depression models.
Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.
Role reference: Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · 2017 ↗
Names you may encounter
PE 22-28 · Spadin analog
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Seven-residue peptide designed from spadin, a sortilin-propeptide fragment; TREK-1 channel blocker in laboratory studies
- Research focus
- TREK-1 blockade in depression models
- Featured evidence
- Cell and animal study
- Source check
- October 4, 2026
Biology & proposed mechanism
Spadin and PE-22-28 block TREK-1, a potassium channel linked to mood regulation in animal research. In engineered human cells, PE-22-28 blocked TREK-1 at a far lower concentration than spadin, and its effect lasted longer in mice. Blocking a channel and changing mouse behavior do not show an antidepressant effect in humans.
Research context & identity
This profile covers preclinical neuroscience research. PE-22-28 has no approved medical use, and no published human trials were found when this page was checked.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Cell and animal study · 2017
Shortened spadin analogs in TREK-1 cells and mouse depression models
What did this publication test, and what did it find?
- Population / model
- Cell lines expressing human TREK-1, mouse cortical neurons, and mice in behavioral depression models.
- Study design
- Patch-clamp channel experiments, then mouse forced-swim and novelty-suppressed feeding tests, neurogenesis and synapse-marker measurements, and duration-of-action comparisons with spadin.
- Main finding
- The authors reported stronger and more selective TREK-1 inhibition than spadin, less immobility in the forced-swim test, a shorter latency to feed after four days, more neurogenesis and synapse-marker expression, and action lasting up to about 23 hours in mice versus about 7 hours for spadin.
- Limits & context
- Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
The publication does not include a human safety assessment. TREK-1 channels occur in many tissues, so effects outside the brain, long-term exposure and interactions remain unknown.
Evidence boundaries
Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
PE-22-28 (10 mg)
American Peptides · Vendor-labeled research use only
$70.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Has PE-22-28 been tested in people?
- What material, population, and route were actually studied?
- Mouse behavior tests are screening models, not a diagnosis of depression. The work comes from the group that discovered spadin, has not been confirmed in human trials, and does not establish a safe or effective use in people.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Has PE-22-28 been tested in people?
Not in the publications checked for this page. Its evidence comes from cell and mouse experiments, and mouse behavior tests cannot show that it treats depression in humans.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.